dapagliflozin / metformin

This medicine is authorised for use in the European Union.


Xigduo is a diabetes medicine used, together with diet and exercise in adults with type 2 diabetes. It contains the active substances dapagliflozin and metformin.

Xigduo is used:

  • on its own in patients whose disease is not controlled well enough with metformin alone;
  • in combination with other diabetes medicines when these medicines together with metformin are not controlling the diabetes well enough.

Xigduo can also be used to replace dapagliflozin and metformin taken as separate tablets.

This EPAR was last updated on 12/02/2020

Authorisation details

Product details
Agency product number
Active substance
  • metformin hydrochloride
  • dapagliflozin propanediol monohydrate
International non-proprietary name (INN) or common name
dapagliflozin / metformin
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
AstraZeneca AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address

SE-151-85 Sodertalje

Product information

11/12/2019 Xigduo - EMEA/H/C/002672 - IG/1171


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Drugs used in diabetes

  • Combinations of oral blood glucose lowering drugs

Therapeutic indication

Xigduo is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:

•    in patients insufficiently controlled on their maximally tolerated dose of metformin alone 
•    in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products
•    in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.

For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
3 ratings
1 rating